A phase I/II study of OSE-172 for the treatment of cancer
Phase of Trial: Phase I/II
Latest Information Update: 28 Mar 2018
At a glance
- Drugs OSE-172 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- 28 Mar 2018 According to an OSE Immunotherapeutics media release, company received a 9.2 million Euro grant from Bpifrance in July as part of a collaborative program (EFFI-CLIN) to support the development of OSE-172.
- 28 Mar 2018 According to an OSE Immunotherapeutics media release, company expects to start clinical phase within the next few months.
- 08 Jan 2018 New trial record